Evaluation of molecular subtypes of breast cancer using MRI BI-RADS Lexicon
Background Molecular subtyping of breast cancer is one of the prognostic factors which play a very important role in managing patient’s treatment plan. The MRI BI-RADS Lexicon is initially used to categorize breast lesions but recent attempts were employed to differentiate breast lesions based on th...
Gespeichert in:
Veröffentlicht in: | Egyptian Journal of Radiology and Nuclear Medicine 2024-12, Vol.55 (1), p.52-16, Article 52 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Molecular subtyping of breast cancer is one of the prognostic factors which play a very important role in managing patient’s treatment plan. The MRI BI-RADS Lexicon is initially used to categorize breast lesions but recent attempts were employed to differentiate breast lesions based on their molecular subtypes using this lexicon. The study aimed to evaluate of the role of the MRI BI-RADS Lexicon in classifying different molecular subtypes of breast cancer especially after coupling with Kaiser scoring system.
Methods
This retrospective study was conducted on 147 patients with 170 malignant breast lesions. They underwent Pre-contrast and a Dynamic contrast MRI study. Retrospective interpretation of the morphological and dynamic criteria of the breast lesions based on the MRI BI-RADS criteria was carried out followed by reassessment of the same lesions by Kaiser scoring. Resulting data were correlated with histopathological and immunological characterization.
Results
Luminal subtypes were more frequently encountered as mass lesions, contrary to the Non-Luminal lesions which showed a more frequent non-mass presentation value (
P
0.002). The shape, margin, internal enhancement pattern of the mass lesions showed significant variability between different molecular subtypes (
P
|
---|---|
ISSN: | 2090-4762 0378-603X 2090-4762 |
DOI: | 10.1186/s43055-024-01206-1 |